drugset
drugset / Trial / NCT05322603

Efficiency and Safety a Fixed Combination of Orphenadrine and Diclofenac for Postoperative Analgesia

NCT05322603 ↗

Completed 60 enrolled Petrovsky National Research Centre of Surgery
RandomizedParallel-groupOpen-labelTreatment

Summary

The study will include 60 patients after cardiac surgery. The first group will include 30 patients who will use the drug Neodolpasse manufactured by Fresenius Kabi, which is a fixed combination of 30 mg of orphenadrine and 75 mg of diclofenac; the second group will consist of 30 patients who will use patient-controlled morphine analgesia (РСА) in the form of monotherapy.

Timeline

Start
2022-03-18
Primary completion
2022-08-20
Completion
2022-08-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Diclofenac Other / unclassified 75 mg Intravenous
Subject Morphine Other / unclassified 1 mg —
Subject Orphenadrine Small molecule 30 mg Intravenous

Indications

No indication recorded.